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Prostate cancer (PCa) is the second most frequent cause of male cancer-related death in the United States of America (USA) and Western Europe. Its incidence is continuously rising, with over 200 000 new cancers and 35 000~40 000 deaths per year, 1 Carcinogenesis and the mechanisms influencing the progression and prognosis of PCa is a multistep process, involving both genetic insults to epithelial cells and changes in epithelial-stromal interactions. 2 Despite extensive research PCa is not understood.
There are two proliferative markers-Ki-67 and proliferating cell nuclear antigen (PCNA). Ki-67 antigen is expressed in proliferative cells throughout the G1, S, G2, and M phases, and provides a reliable index of cellular proliferation 3, 4 PCNA is an acidic nuclear protein, expressed mainly in phase S of the cellular cycle. It becomes active, in various tissues par-ticularly in nervous tissue, as a first response to multiple insults. 5.6 Recent studies have demonstrated that identification of proliferative activity in a tumour may predict the biological behaviour. 7, 8 There are no reports of the relation between proliferating activity and clinical aspects of PCa. Therefore, to investigate the potential of Ki-67 and PCNA on the early diagnosis of PCa, we observed the expression of these markers in PCa and benign prostatic hyperplasia (BPH).
Methods
Human prostate carcinoma cell line LNCaP, hormone dependent (ATCC # CRL-1740), human prostate carcinoma cell line PC-3, hormone independent (ATCC # CRL-1435), and human normal prostate epithelial cell line HuPEC (ATCC # CRL-1059) were used. Cell lines were maintained in Opti-MEMR I medium supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine at 37 °C in 5% CO2
Approval was obtained from the local research and ethics committee for use of tissue. Specimens were obtained from patients (121 with PCa, 45 with BPH and 36 normal cases) undergoing transurethral resection of the prostate (TURP) or transvesical prostatectomy (TP) for BPH, or TURP or radical prostatectomy (RP) as treatment for PCa at the Urinary Surgery Department of First Municipal People's Hospital, Guangzhou Medical College, GuangDong, P.R.China and The Fourth PLA Medical University, Xi'an, P.R.China. None of the patients had undergone chemotherapy or radiotherapy before surgery. The age of the patients, maximum tumour size, depth of wall invasion and histological gradeing were obtained from histopathology reports. Staging of PCa was done according to the Tumour-Node-Metastasis Stage Grouping. 9 MTT, DMSO, and DNase I were purchased from Sigma. Opti-MEMR I reduced-serum medium and Trizol were from Gibco-BRL Life Technologies. Plasmid Purification Kit was from Qiagen. All chemicals, reagents and solvents were of the highest grade available and were used as directed by the manufacturers. Distilled water used was obtained in our laboratory by an ion-exchange and distillation process.
RNA isolation
Total RNA was extracted from the LNCaP, PC-3 and HuPEC pellets, and the human tissues with a phenol/ guanidine isothiocyanate-based reagent (Trizol TM , Gibco-BRL, Scotland.). Briefly, 1 ml Trizol and 200 µl chloroform were added to each tube. The RNA was then precipitated with 500µl isopropanol (v/v) and washed with 75% ethanol and air-dried. The purified RNA was then dissolved in 10 µl diethyl pyrocarbonate (DEPC)-treated water, optical density measured at 260/280 wavelength and stored at -80℃ prior to use in the synthesis of cDNA.
Fluorimeter-based RT-PCR
RNA was reverse transcribed using the Superscripte TM Preamplification System (Life Technology). 500ng total RNA were mixed with 500ng oligo (dT) primers and incubated at 70℃ for 10 min. The mixture was then chilled on ice and incubated with a 1× reverse transcriptase buffer (50 mM Tris-HCl, pH 8. 
Quantitative determination of Ki-67 and PCNA mRNA
Sample quantification was carried out with Sequence Detection System (SDS2.0) software and constructing a standard calibration curve using serial dilutions of plasmid β-actin DNA of known concentration, from which the concentration of an unknown sample could be determined. To assay inter-assay variation, a least square curve fitting test was used to construct a fit, and the standard error of the data points to the curve was estimated by plotting the log of the sample concentration against the number of cycles the PCR machine undertakes to yield a set of fluorescent data. The standard error was estimated to be 15% on the log and was within the values described forβ-actin quantification using competitive PCR.
Immunohistochemistry Staining and Assessment
For immunohistochemistry, tissues were fixed in 10% buffered formalin and embedded in paraffin. Commercially available monoclonal antibodies to PCNA and Ki-67 were used. Immunohistochemical staining was carried out on TMA sections using the avidinbiotin method and a commercially available kit (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, CA). One paraffin-embedded block of tumour tissue was selected from each case and cut into 4µm sections. Deparaffinized sections were treated with methanol containing 3% hydrogen peroxide for 10 min before antigen retrieval using a microwave oven at 95℃ for 5 min and cooling at 25℃ for 2 hr. After washing with phosphate-buffered saline, blocking serum was applied for 10 min. The sections were incubated with an anti-PCNA monoclonal antibody and an anti-Ki-67 monoclonal antibody overnight at 4℃. After washing in phosphate-buffered saline, a biotin-marked secondary antibody was applied for 10 min followed by a peroxidase-marked streptavidin for an additional 10 min. The reaction was visualized using 3, 3'-diaminobenzidine tetrahydrochloride. The nuclei were counterstained with hematoxylin. Positive and negative immunohistochemistry controls were routinely used. Reproducibility of staining was confirmed by re-immunostaining via the same method in multiple, randomly selected specimens.
To determine the expression of PCNA and Ki-67, two experienced pathologists independently examined staining while blind to the clinicopathologic data and clinical outcomes of the patients. The number of positive cells that showed immunoreactivity on the cell nucleus in the representative ten microscopic fields was counted and the percentage of positive cells was calculated.
Statistical analysis
The labeling indices of PCNA and Ki-67 were counted. The mean and the standard deviation (SD) were calculated. SPSS12.0 software was used for all statistical data analyzed by the unpaired t-test. The selected level of significance was P < 0.05.
Results

RNA isolation
The purity of RNA extracted from the LNCaP, PC-3 and HuPEC pellets, and human tissues of PCa, BPH and normal cases was very high according to the ratio value of OD260/OD280, which was ranged from 1.9 to 2.0. Therefore, this RNA could be used for following RT-PCR test. Threshold cycle (Ct) was defined as the cycle number at which the fluorescence signal passed the noise band. Using the standard curve, amplification of input cDNA templates of Ki-67 and PCNA in the ABI 7900HT was quantified. Curve correlation was good, R 2 > 0.99.
The quantitative results of Ki-67 and PCNA mRNA expressed in LNCaP, PC-3, HuPEC cell lines and in the human tissues from patients with PCa, BPH and normal cases are shown in Table 1 and Table 2 .
The ratios of PCNA and Ki-67 expression in the PCa cell lines were higher (P=0.05, P<0.01) than in the normal human prostate cell line. Moreover, the two makers were differentially expressed in three kinds of tissues and the increased expression appeared in PCa (P<0.05) and BPH (P<0.05) tissues, relative to human normal prostate tissues. Compared with BPH, the ratio of Ki-67 and PCNA expressed in tumour was more than that in BPH (P<0.05), but the increasing extent of Ki-67 was larger than that of PCNA, which was the same as changes in PCa cell lines in vitro.
Association of Ki-67 and PCNA expression with the clinical stages of PCa is also shown in Table 2 
Discussion
PCa is one of the most serious of carcinomas. Resistance to hormone therapy is related to a considerable proportion of PCa deaths with few therapeutic options available thereafter. 10, 11 Recently, molecular tests for cancer cell-associated genes and other genetic markers, being direct indicators of the presence of the cancer cells in the biological specimen, have been predicted to provide improvement in diagnostic specificity 12, 13 As the growth rate of tumour tissue is determined by proliferative activity and cell death, expression of two proliferative makers--Ki-67 and PCNA were examined in this study to enhance the facility and accuracy of early diagnosis of PCa.
Ki-67 and PCNA labeling indices showed different results. First, they were expressed more in PCa cell lines (LNACaP and PC-3) than in normal prostate epithelial cells. Moreover, up-regulation of Ki-67 in the PC3 cell line was different from that in the LNACaP cell line, which was more distinctive than the latter. This may be due to the proliferation rate of PC3 cell line (passage every day in our lab) is faster than LNACaP cell line (passage every 6 or 7 days in our lab). Second, increased expression of the two markers was demonstrated in PCa and BPH tissues. Third, compared with BPH, increased expression of Ki-67 and PCNA was shown in PCa tissues. The increase of Ki-67 was larger than that of PCNA, which was the same as changes in PCa cell lines in vitro. This suggests that expression of Ki-67 was more sensitive in reflecting the rate of cell proliferation in PCa tissues, which is similar to previous reports. 14, 15 The Ki-67 antigen is useful for identifying proliferative cells. Although flow cytometry methods showed that Ki-67 is expressed in all cell cycle phases except G0 phase, its detection by immunohistochemical methods is limited to its appearance in the late G1 phase with maximum expression in prophasis and metaphases. 16 Immunoexpression then diminishes in anaphase and telophase, levels being undetectable during most of the interphase. Thus, Ki-67 is considered as a mitotic activity indicator. An increase in Ki-67 expression indicates a rise of the mitotic activity and of the cell proliferation. Moreover, PCNA is a 36-kd DNA polymerase delta auxiliary protein that complexes with cyclin D and cyclin-dependent kinases. It is involved in the proliferation of neoplastic as well as non-neoplastic cells and it is specifically expressed in proliferating cell nuclei. This specific antibody recognizes PCNA protein, which is at tits maximum level in late G1 and S phases of proliferating cells. 17, 18 However, there has been controversy about the diagnostic impact of PCNA. Ray et al 19 demonstrated that the PCNA index was correlated with necrosis, high grade atypia, cellularity and mitotic rate. In contrast, Sbasching et al 20 did not find correlation of PCNA expression with survival in GIST. In order to find a more reliable index for the early diagnosis of PCa, our group investigated the changes of ratio value of Ki-67 and PCNA expression in different tissues. We found that the ratio of two markers increased following the grading of PCa and there were differences in PCa, BPH and normal prostate tissues.
In conclusion, this study suggests that Ki-67 and PCNA as proliferating markers should be combined and their ratio may be more effective and more accurate in the early diagnosis of PCa.
